Panel Discussion: Practical Considerations in Cross-Border Transactions Amid Geopolitical & Market Uncertainty

• Evaluate how public policy shifts, geopolitical uncertainty, and changes across the international biopharma landscape are reshaping transaction structures, negotiations, and deal execution
• Future-proof cross-border transactions by building flexibility into deal terms, governance frameworks, and risk allocation mechanisms amid continued market uncertainty
• Strengthen diligence and decision-making when evaluating international assets, partners, and opportunities while preparing for emerging trends in cross-border dealmaking

Speakers:

Daryl Kreml

Head of Ethics & Compliance

Takeda Oncology

Michael Bookman

CLO

Immuneering Corp.

Iya Kessler

General Counsel & Corporate Secretary

Arbor Biotechnologies, Inc.

Alan Tamarelli

Chair, Life Sciences Transactions

Paul Hastings